Opthea Ltd represents a strong commitment to advancing the field of ophthalmology and improving patients' quality of life. Their corporate philosophy revolves around innovation, research, and development of novel therapies for eye diseases. Opthea Ltd firmly believes in collaboration with leading experts, healthcare providers, and regulatory authorities to drive the successful commercialization of their cutting-edge products. Their unwavering dedication to scientific excellence ensures the delivery of safe and effective treatments for various ocular conditions. Opthea Ltd's passion for helping patients regain and maintain vision health shines through their continuous pursuit of groundbreaking solutions in the field of ophthalmic medicine.

Opthea Ltd is primarily present in Australia, the United States, and Europe.

Opthea Ltd, a leading biotechnology company, has achieved significant milestones in recent years. Notably, Opthea successfully completed Phase 2b clinical trials for its novel therapy OPT-302, used in combination with Eylea, for treating wet age-related macular degeneration (AMD). The results showed a remarkable improvement in visual acuity and a reduction in the rate of disease progression. Furthermore, Opthea received fast-track designation from the U.S. FDA for OPT-302, acknowledging its potential in treating AMD. These achievements position Opthea as a promising player in the field, with the potential to address a critical need in the ophthalmology market.

Opthea Ltd is a biotechnology company specializing in the development and commercialization of novel therapies for eye diseases. Founded in 1986, Opthea has amassed a rich history of scientific innovation and breakthroughs in the field of ophthalmology. The company is committed to transforming the lives of patients through its cutting-edge research and development efforts. Opthea's dedication to advancing treatments for conditions such as wet age-related macular degeneration (AMD) and diabetic macular edema has garnered significant attention within the medical community. With a strong focus on patient outcomes, Opthea Ltd continues to revolutionize the landscape of eye care worldwide.

The main competitors of Opthea Ltd in the market include pharmaceutical companies such as Regeneron, Novartis, and Genentech. These companies also specialize in developing treatments for eye diseases and have established products in the market.

Opthea Ltd is primarily active in the biotechnology and pharmaceutical industries.

Opthea Ltd operates under a unique business model. This biopharmaceutical company primarily focuses on the development of novel therapies for the treatment of eye diseases. Opthea aims to address unmet medical needs, particularly in the field of ophthalmology, by leveraging its expertise in the fields of VEGF (Vascular Endothelial Growth Factor) biology and protein engineering. By developing innovative and effective treatments, Opthea strives to improve the lives of patients suffering from vision-related disorders. With their commitment to advancing cutting-edge research and therapies, Opthea Ltd has positioned itself as a key player in the ophthalmic pharmaceutical industry.

Opthea KGV ir -1,23.

Opthea KUV ir 2165,03.

AlleAktien kvalitātes vērtējums Opthea ir 7/10.

Opthea apgrozījums ir 124 670,00 USD.

Opthea peļņa ir -220,24 milj. USD.

Opthea Ltd is a leading biopharmaceutical company specializing in the development of ocular therapeutics. The company's business model focuses on the development of drugs for the treatment of eye diseases such as Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Neovascular (wet) AMD (nAMD). Opthea aims to expand the use of its proprietary technology platform to develop drugs that target various proteins. The company focuses on developing therapies based on biologically derived immune proteins. Opthea conducts detailed clinical studies and works on optimizing and refining its available technology to provide the best possible medication. The company has three main products: OPT-302, OPT-822, and OPT-821. OPT-302 is a novel immune protein with anti-VEGF and anti-PIGF activities specifically developed as a therapy for nAMD. OPT-822 is another immune protein specifically developed for the prevention of Diabetic Retinopathy. OPT-821 is an immune protein currently being tested in the preclinical phase for the treatment of AMD. Opthea's valuable assets lie in the development of these technologies. By strategically developing different immune proteins for the treatment of various eye diseases, the likelihood of success in drug development increases. Furthermore, the broad product portfolio reduces investor risk. Opthea has expanded its presence in the United States, Europe, and Asia. The company has formed intensive partnerships with various companies, research institutions, clinics, and organizations. For example, Merck is involved, and Novartis is in the final stages of acquiring the company. Another component of Opthea's business model is continuous development, relying on state-of-the-art technologies and methods. With a high scientific expertise in the field of ophthalmology, the company has made a name for itself among international investors. Ongoing research and development are part of the program to achieve the best possible results. In summary, Opthea's business model is based on the development of drugs for the treatment of eye diseases such as AMD and nAMD. The company has an advanced technology platform for producing biological antibody products targeting various proteins. Opthea offers a comprehensive product range to address different objectives in the market, and the company is committed to maintaining a high level of manufacturing expertise. Through industry-specific partnerships, Opthea has gained a strong position in the ophthalmic industry and aims for further expansion.

Opthea izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Opthea vai uzņēmums nedod dividendes.

Opthea ISIN ir AU000000OPT2.

Opthea WKN ir A2AB8J.

Opthea simbols ir OPT.AX.

Pēdējo 12 mēnešu laikā Opthea maksāja dividendes 0,15 USD apmērā. Tas atbilst aptuveni 34,67 % dividendes ražībai. Nākamajos 12 mēnešos Opthea plāno maksāt dividendes -0,05 USD apmērā.

Opthea pašreizējā dividendu rentabilitāte ir 34,67 %.

Opthea maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Opthea pēdējo 4 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā -0,05 USD. Tas atbilst dividendes ražībai -11,95 %.

Opthea tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Opthea apmērā 0,15 USD, kas tika izmaksāta 24.02.2005., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 4.02.2005..

Pēdējās dividendes izmaksa notika 24.02.2005..

Gadā 2023, Opthea izmaksāja 0 USD dividendes.

Opthea dividendes tiek izmaksātas USD.